A meta-analysis about the relationship of serum nesfatin-1 levels in patients with type 2 diabetes mellitus
Abstract
Introduction. Nesfatin-1, a peptide coded by the NUCB2 gene, has recently been implicated in the regulation of insulin synthesis and glucose homeostasis. These findings suggest a potential role for nesfatin-1 in the etiology of type 2 diabetes mellitus.
Objective. To analyze the relationship between circulating levels of nesfatin-1 and type 2 diabetes mellitus.
Materials and methods. We used PubMed, Scopus, and DOAJ platforms to search published articles from 2012 to 2024. The keywords used were “diabetes mellitus”, “diabetes”, “type 2 diabetes”, “nesfatin-1”, “NUCB2”, “ELISA”, “plasma”, and “serum”. We included all case-control and cross-sectional studies conducted in humans, with full-text availability, and written in English or Spanish.
Results. We included eight studies comprising 305 patients with type 2 diabetes mellitus and 205 controls. The results showed a significant relationship between nesfatina-1 and type 2 diabetes mellitus with a high heterogeneity index (t2 = 3.91; χ2 = 349.63, p < 0.00001; I2 = 98%).
Conclusions. The results show a significant relationship between nesfatin-1 and type 2 diabetes mellitus, supporting its potential use as a biomarker for this disease
Downloads
References
1. World Health Organization. Diabetes. Fecha de consulta: 2 de mayo de 2024. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/diabetes
2. International Diabetes Federation. IDF Diabetes Atlas. 10th edition. Bruselas: Edition Committee; 2024. Fecha de consulta: 2 de mayo de 2024. Disponible en: https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf
3. National Institute of Diabetes and Digestive and Kidney Diseases. Risk factors for type 2 diabetes. Washington: NIDKK; 2022. Fecha de consulta: 3 de mayo de 2024. Disponible en: https://www.niddk.nih.gov/health-information/diabetes/overview/risk-factors-type-2-diabetes
4. Petrie JR, Boyle JG. Diabetes mellitus. In: Davidson’s Principles and Practice of Medicine. 24th edition. London: Elsevier; 2023. p. 703-53. Fecha de consulta: 2 de mayo de 2024. Disponible en: https://www.clinicalkey.es/!/content/book/3-s2.0-B9780702083471000211?scrollTo=%23hl0003261
5. Asociación Latinoamericana de Diabetes. Guías ALAD sobre el diagnóstico, control y tratamiento de la diabetes mellitus tipo 2 con medicina basada en evidencia. 9a edición. México: Rev ALAD; 2019. Fecha de consulta: 2 de mayo de 2024. Disponible en: https://www.revistaalad.com/guias/5600AX191_guias_alad_2019.pdf
6. Pałasz A, Krzystanek M, Worthington J, Czajkowska B, Kostro K, Wiaderkiewicz R, et al. Nesfatin-1, a unique regulatory neuropeptide of the brain. Neuropeptides. 2012;46:105-12. https://doi.org/10.1016/j.npep.2011.12.002
7. Luo JJ, Wen FJ, Qiu D, Wang SZ. Nesfatin-1 in lipid metabolism and lipid-related diseases. Clin Chim Acta. 2021;522:23-30. https://doi.org/10.1016/j.cca.2021.08.005
8. Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, et al. Identification of Nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443:709-12. https://doi.org/10.1038/nature05162
9. Dore R, Krotenko R, Reising JP, Murru L, Sundaram SM, Di Spiezio A, et al. Nesfatin-1 decreases the motivational and rewarding value of food. Neuropsychopharmacology. 2020;45:1645-55. https://doi.org/10.1038/s41386-020-0682-3
10. Chen X, Dong J, Jiao Q, Du X, Bi M, Jiang H. “Sibling” battle or harmony: Crosstalk between nesfatin-1 and ghrelin. Cell Mol Life Scis. 2022;79:169. https://doi.org/10.1007/s00018-022-04193-6
11. Shimizu H, Oh IS, Okada S, Mori M. Nesfatin-1: An overview and future clinical application. Endocr J. 2009;56:537-43. https://doi.org/10.1507/endocrj.k09e-117
12. Xu Y, Chen F. Antioxidant, anti-inflammatory, and anti-apoptotic activities of nesfatin-1: A review. J Inflamm Res. 2020:13:607-17. https://doi.org/10.2147/JIR.S273446
13. Gharanei S, Ramanjaneya M, Patel AH, Patel V, Shabir K, Auld C, et al. NUCB2/nesfatin-1 reduces obesogenic diet induced inflammation in mice subcutaneous white adipose tissue. Nutrients. 2022;14:1409. https://doi.org/10.3390/nu14071409
14. López-Gómez A, Martínez-Cordero C. Nesfatina-1: una nueva hormona anorexigénica. Hosp Med Clin Manag. 2018;11:130-6.
15. Kadim BM, Hassan EA. Nesfatin-1 as a diagnosis regulatory peptide in type 2 diabetes mellitus. J Diabetes Metab Disord. 2022;21:1369-75. https://doi.org/10.1007/s40200-022-01070-8
16. Algul S, Ozkan Y, Ozcelik O. Serum nesfatin-1 levels in patients with different glucose tolerance levels. Physiol Res. 2016;65:979-85. https://doi.org/10.33549/physiolres.933186
17. Li XS, Yan CY, Fan YJ, Yang JL, Zhao SX. NUCB2 polymorphisms are associated with an increased risk for type 2 diabetes in the Chinese population. Ann Transl Med. 2020;8:290. https://doi.org/10.21037/atm.2020.03.02
18. Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept. 2010;159:72-7. https://doi.org/10.1016/j.regpep.2009.11.003
19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021;74:790-9. https://doi.org/10.1016/j.rec.2021.07.010
20. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. La Escala Newcastle-Ottawa (NOS) para evaluar la calidad de estudios no aleatorios en metanálisis. Ottawa: Ottawa Hospital Research Institute; 2021.
21. Rostom A, Dubé C, Cranney A, Saloojee N, Garritty C, Sampson M, et al. Appendix D: Quality assessment forms. In: Cochrane handbook for systematic reviews of interventions. Rockville (MD): Agency for Healthcare Research and Quality; 2004. Fecha de consulta: 2 de mayo de 2024. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK35156/
22. Review Manager (RevMan) [software]. Version 5.3. Copenhaguen: The Nordic Cochrane Center, The Cochrane Collaboration; 2020. Fecha de consulta: 2 de mayo de 2024. Disponible en: https://revman.cochrane.org
23. Epidat: programa para análisis epidemiológico de datos, Versión 3.1. [software]. Santiago de Compostela (ES): Consellería de Sanidade, Xunta de Galicia; 2006. Fecha de consulta: 13 de mayo de 2024. Disponible en: https://www.sergas.es/Saude-publica/EPIDAT-3-1?idioma=es
24. Tamayo y Orozco JA, Lastiri-Quirós HS. La enfermedad renal crónica en México. Hacia una política nacional para enfrentarla. México: Academia Nacional de Medicina de México; 2016. Fecha de consulta: 13 de mayo de 2024. Disponible en: https://www.anmm.org.mx/publicaciones/ultimas_publicaciones/ENF-RENAL.pdf
25. Martínez-Escalante JE, Romero-Ibargüengoitia ME, Plata-Álvarez H, López-Betancourt G, Otero-Rodríguez R, Garza-Cantú A, et al. Pie diabético en México: factores de riesgo para mortalidad posterior a una amputación mayor, a 5 años, en un hospital de salud pública de segundo nivel. Cir Cir. 2021;89:284-90. https://doi.org/10.24875/CIRU.20000209
26. Instituto Nacional de Estadística y Geografía. Estadísticas a propósito del día mundial de la diabetes (14 de noviembre). México: INE; 2021. Fecha de consulta: 13 de mayo de 2024. Disponible en: https://www.inegi.org.mx/contenidos/saladeprensa/aproposito/2021/EAP_Diabetes2021.pdf
27. Mirakhor-Samani S, Ghasemi H, Rezaei-Bookani K, Shokouhi B. Serum nesfatin-1 level in healthy subjects with weight-related abnormalities and newly diagnosed patients with type 2 diabetes mellitus: A case-control study. Acta Endocrinol (Buchar). 2019;5:69-73. https://doi.org/10.4183/aeb.2019.69
28. Matta RA, El-Hini SH, Eldin Salama AM, Moaness HM. Serum nesfatin-1 is a biomarker of pre-diabetes and interplays with cardiovascular risk factors. Egypt J Intern Med. 2022;34:15. https://doi.org/10.1186/s43162-022-00106-y
29. Khalil UA, Mohamed OE, Abdullah AA, Fawzy MS, Rashad NM, Samir GM. Do serum nesfatin-1 levels have a predictive role in type-2 diabetes mellitus and its microvascular complications? A case-control study. Cureus. 2024;16:e53007. https://doi.org/10.7759/cureus.53007
30. Huang K, Liang Y, Wang K, Wu J, Luo H, Yi, B. Influence of circulating nesfatin-1, GSH, and SOD on insulin secretion in the development of T2DM. Front Public Health. 2022;10:882686. https://doi.org/10.3389/fpubh.2022.882686
31. Abed BA, Farhan LO, Dawood AS. Relationship between serum nesfatin-1, adiponectin, resistin concentration, and obesity with type 2 diabetes mellitus. Baghdad Sci J. 2023;21:0117. https://doi.org/10.21123/bsj.2023.8119
32. Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120:91-5. https://doi.org/10.1055/s-0031-1286339
Some similar items:
- Jack Roberto Silva-Fhon, Violeta Magdalena Rojas-Huayta, Juan Pablo Aparco-Balboa, Bernardo Céspedes-Panduro, Rosalina Aparecida Partezani-Rodrigues, Sarcopenia and blood albumin: A systematic review with meta-analysis , Biomedica: Vol. 41 No. 3 (2021)
- José Moreno, Fernando De la Hoz, Alejandro Rico, Karol Cotes, Alexandra Porras, Flu vaccine effectiveness: a metaanalysis , Biomedica: Vol. 29 No. 1 (2009)
- Juan Carlos Miguel, Ariana Erazo, Fernanda Beduino, Juan Carlos Picena, María Isabel Luciano, Gustavo Pizzuti, María Cristina Tarrés, Silvana Montenegro, Stella Maris Martínez, Chronic bronchial dilatations in different colonies of laboratory rats , Biomedica: Vol. 22 No. 2 (2002)
- Adriana Guzmán, Esteban Navarro, Leidy Obando, Jorge Pacheco, Korina Quirós, Leticia Vásquez, Milena Castro, Fernando Ramírez, Effectiveness of interventions for the reversal of a metabolic syndrome diagnosis: An update of a meta-analysis of mixed treatment comparison studies , Biomedica: Vol. 39 No. 4 (2019)
- Carmen Lucía Curcio, Andrés Fernando Giraldo, Fernando Gómez, The healthy aging phenotype in older people in Manizales , Biomedica: Vol. 40 No. 1 (2020)
Copyright (c) 2025 Biomedica
This work is licensed under a Creative Commons Attribution 4.0 International License.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
